Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...
1INCY : Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease...
Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary ...
Tagtik4d
70 million people affected by skin disease
An autoimmune disease characterized by skin depigmentation, vitiligo has attained many stereotypes. This dermatological ...
Harnessing the gut microbiome to halt vitiligo patches
New research shows gut-friendly bacteria may slow vitiligo progression, offering hope for millions with autoimmune disease.
Dermatology Advisor6d
Certain Comorbidities Are More Significant in Patients With Dermatologic Disease
Higher rates of venous thromboembolism, lymphoma, and infections were observed in those with atopic dermatitis and psoriasis vs control patients.
FMIBlog6d
Dermatology Lasers Market to Reach USD 3,487.8 Billion by 2033 at a 7.0% CAGR, Driven by Rising Skin Disease Awareness and Cosmetic Advancements
The global dermatology lasers market is set for substantial growth, increasing from USD 1,767.8 billion in 2023 to USD ...